Navigation Links
BioElectronics Corporation Announces Singapore and Malaysia Sales

FREDERICK, Md., Aug. 28 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that Astonix Life Science, has signed a sales and distribution agreement to provide ActiPatch Therapy to the healthcare market in Singapore. The initial order has been shipped and introduction of ActiPatch to the market has been warmly received.

The interest in the benefits of ActiPatch by the Healthcare providers in Singapore has been strong enough to allow Astonix Life Science to move forward in their plan to increase their distribution territory ahead of schedule. They have recently signed an additional agreement for the healthcare market in Malaysia.

"At Astonix Life Science, we are driven by innovations in life sciences. We are proud to be the distributor of ActiPatch. Being able to offer ActiPatch to these markets is an important healing benefit. We are extremely proud to be associated with BioElectronics and the people behind ActiPatch," said Amelia Chew, Director of Astonix Life Science.

"The enthusiasm shown by Astonix Life Science in introducing ActiPatch to the Singapore healthcare market has generated a reciprocal excitement at BioElectronics. We are looking forward to a strong joint commitment to provide the accelerated healing benefits of ActiPatch to the people of Singapore and Malaysia," said Andrew Whelan, President of BioElectronics Corporation.

About BioElectronics:

BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for a few cents per hour. The unique ActiPatch delivery system, using patented technology, provides a cost- effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit

Safe Harbor Statement:

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.

SOURCE BioElectronics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Speaker announces business members of IT Task Force
11. Doyle announces technology tax credits for Berbee
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):